Press release from Companies
Publicerat: 2026-02-18 09:10:00
Inhalation Sciences Sweden AB (ISAB) today announces that it has received an order valued at approximately EUR 139,000 (approximately SEK 1.5 million) for an IRS (Inhalation Research Services) for DissolvIt® from a recurring customer and major international pharmaceutical company. The company is a global developer and manufacturer of complex generics and specialty medicines, with a strong presence in both established and emerging markets, that will use ISAB’s technology to generate high-quality preclinical data for inhaled drug formulations.
The project includes DissolvIt® studies on several test items, with method optimisation and repeated experiments for reliability carried out at Inhalation Sciences’ laboratories at Novum Science Park in Huddinge, Sweden
DissolvIt® is ISAB’s proprietary in vitro dissolution-absorption system, designed to closely mimic the environment of the human lung. By combining precise aerosol deposition via PreciseInhale® with a dynamic flow-through dissolution and absorption setup, DissolvIt® enables detailed and physiologically relevant characterization of inhaled formulations, for both new chemical entities and generic products.
“We are pleased that such a leading global pharmaceutical company has chosen to use our DissolvIt platform again for this important inhalation study. This order confirms the growing recognition of our advanced in vitro technologies as a key resource for generating decision-critical data in inhalation drug development, from early-stage candidate selection through to rigorous comparison of generic formulations”, says Manoush Masarrat, CEO of Inhalation Sciences.
For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.
This disclosure contains information that Inhalation Sciences is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on February 18, 2026 at 09:10.
